Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Horvath, A; Traub, J; Aliwa, B; Bourgeois, B; Madl, T; Stadlbauer, V.
Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis.
NUTRIENTS. 2022; 14(4): Doi: 10.3390/nu14040748 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Horvath Angela

Stadlbauer-Köllner Vanessa

Co-authors Med Uni Graz

Aliwa Benard

Bourgeois Benjamin Michel Rene

Madl Tobias

Traub Julia

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

L-ornithine L-aspartate (LOLA) is administered as a therapeutic and/or preventive strategy against hepatic encephalopathy either intravenously or orally in patients with liver cirrhosis. Here, we analyzed how LOLA influences the microbiome and metabolome of patients with liver cirrhosis. We retrospectively analyzed the stool microbiome, stool, urine and serum metabolome as well as markers for gut permeability, inflammation and muscle metabolism of 15 cirrhosis patients treated orally with LOLA for at least one month and 15 propensity-score-matched cirrhosis patients without LOLA. Results were validated by comparing the LOLA-treated patients to a second set of controls. Patients with and without LOLA were comparable in age, sex, etiology and severity of cirrhosis as well as PPI and laxative use. In the microbiome, Flavonifractor and Oscillospira were more abundant in patients treated with LOLA compared to the control group, while alpha and beta diversity were comparable between groups. Differences in stool and serum metabolomes reflected the pathophysiology of hepatic encephalopathy and confirmed LOLA intake. In the urine metabolome, ethanol to acetic acid ratio was lower in patients treated with LOLA compared to controls. LOLA-treated patients also showed lower serum levels of insulin-like growth factor (IGF) 1 than patients without LOLA. No differences in gut permeability or inflammation markers were found. A higher abundance of Flavonifractor and Oscillospira in LOLA-treated patients could indicate LOLA as a potential microbiome modulating strategy in patients with liver disease. The lower levels of IGF1 in patients treated with LOLA suggest a possible link between the pathophysiology of hepatic encephalopathy and muscle health.

Find related publications in this database (using NLM MeSH Indexing)

Dipeptides - administration & dosage

Humans - administration & dosage

Liver Cirrhosis - complications

Metabolome - administration & dosage

Microbiota - administration & dosage

Retrospective Studies - administration & dosage

Find related publications in this database (Keywords)

microbiome

metabolome

L-ornithine-L-aspartate

cirrhosis

hepatic encephalopathy

© Med Uni Graz • Imprint